Abstract
The promoter for human telomerase reverse transcriptase (hTERTp) is preferentially active in malignant cells. It was recently used to control the expression of the adenoviral E1A gene for the development of oncolytic adenoviruses. To ensure maximal repression in normal cells, the inclusion of additional E-boxes in the proximal region of the core promoter was described. We found that the transcriptional activity of this artificial sequence (T-255-4DEB) is minimal in normal cells, but it is also reduced in all the cancer cell lines tested. The cancer specificity of a new oncolytic adenovirus based in this promoter (AdTE1) was evaluated by direct comparison with wild-type adenovirus type 5 (AdWT) in vitro and in vivo. In all the parameters tested, AdTE1 was attenuated in normal cells, but the efficacy in cancer cells showed a parallel reduction, suggesting a lack of specificity. However, the cytotoxicity of AdTE1 was repressed in senescent cells compared to AdWT. Therefore, we conclude that AdTE1 is preferentially attenuated only in cells that are permanently devoid of telomerase expression such as senescent cells. Further modifications in the telomerase-based promoters should be introduced in order to combine maximal attenuation of oncolytic adenoviruses in normal tissues and enhanced activity in tumors.
Similar content being viewed by others
References
Shenk T (1996) Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM (eds) Fields of virology. Lippincott-Raven, Philadelphia, PA, pp 2111–2147
Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J et al (1999) A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 10:1721–1733
Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S et al (2002) E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 5:627–634
Greider CW (1996) Telomere length regulation. Annu Rev Biochem 65:337–365
Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J et al (1997) Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955–959
Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD et al (1997) hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785–795
Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK et al (1997) Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 6:2011–2019
Cech TR (2004) Beginning to understand the end of the chromosome. Cell 116:273–279
Blackburn EH (2001) Switching and signaling at the telomere. Cell 106:661–673
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015
Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787–791
Wright WE, Tesmer VM, Huffman KE, Levene SD, Shay JW (1997) Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev 11:2801–2809
Shay JW, Wright WE (2000) Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol 1:72–76
Ramakrishnan S, Eppenberger U, Mueller H, Shinkai Y, Narayanan R (1998) Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 58:622–625
Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M (1998) Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 58:1558–1561
Cong YS, Wright WE, Shay JW (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66:407–425 (table of contents)
Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M et al (2000) Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28:669–677
Crowe DL, Nguyen DC, Tsang KJ, Kyo S (2001) E2F-1 represses transcription of the human telomerase reverse transcriptase gene. Nucleic Acids Res 29:2789–2794
Crowe DL, Nguyen DC (2001) Rb and E2F-1 regulate telomerase activity in human cancer cells. Biochim Biophys Acta 1518:1–6
Lin SY, Elledge SJ (2003) Multiple tumor suppressor pathways negatively regulate telomerase. Cell 113:881–889
Wang S, Zhu J (2003) Evidence for a relief of repression mechanism for activation of the human telomerase reverse transcriptase promoter. J Biol Chem 278:18842–18850
Dessain SK, Yu H, Reddel RR, Beijersbergen RL, Weinberg RA (2000) Methylation of the human telomerase gene CpG island. Cancer Res 60:537–541
Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC (1999) DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 59:6087–6090
Cong YS, Bacchetti S (2000) Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem 275:35665–35668
Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, Maida Y et al (2001) Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 29:3006–3011
Won J, Chang S, Oh S, Kim TK (2004) Small-molecule-based identification of dynamic assembly of E2F-pocket protein–histone deacetylase complex for telomerase regulation in human cells. Proc Natl Acad Sci U S A 101:11328–11333
Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M et al (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59:551–557
Horikawa I, Cable PL, Afshari C, Barrett JC (1999) Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 59:826–830
Cong YS, Wen J, Bacchetti S (1999) The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8:137–142
Ducrest AL, Szutorisz H, Lingner J, Nabholz M (2002) Regulation of the human telomerase reverse transcriptase gene. Oncogene 21:541–552
Kirch HC, Ruschen S, Brockmann D, Esche H, Horikawa I, Barrett JC et al (2002) Tumor-specific activation of hTERT-derived promoters by tumor suppressive E1A-mutants involves recruitment of p300/CBP/HAT and suppression of HDAC-1 and defines a combined tumor targeting and suppression system. Oncogene 21:7991–8000
Masutomi K, Yu EY, Khurts S, Ben-Porath I, Currier JL, Metz GB et al (2003) Telomerase maintains telomere structure in normal human cells. Cell 114:241–253
Lanson NA Jr, Friedlander PL, Schwarzenberger P, Kolls JK, Wang G (2003) Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res 63:7936–7941
Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL (2003) Telomerase-dependent oncolytic adenovirus for cancer treatment. Gene Ther 10:1241–1247
Huang Q, Zhang X, Wang H, Yan B, Kirkpatrick J, Dewhrist MW et al (2004) A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin Cancer Res 10:1439–1445
Irving J, Wang Z, Powell S, O’Sullivan C, Mok M, Murphy B et al (2004) Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 11:174–185
Wirth T, Zender L, Schulte B, Mundt B, Plentz R, Rudolph KL et al (2003) A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res 63:3181–3188
Su CQ, Sham J, Xue HB, Wang XH, Chua D, Cui ZF et al (2004) Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol 130:591–603
Zou W, Luo C, Zhang Z, Liu J, Gu J, Pei Z et al (2004) A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 23:457–464
Kim E, Kim JH, Shin HY, Lee H, Yang JM, Kim J et al (2003) Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther 14:1415–1428
Kawashima T, Kagawa S, Kobayashi N, Shirakiya Y, Umeoka T, Teraishi F et al (2004) Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 10:285–292
Horikawa I, Cable PL, Mazur SJ, Appella E, Afshari CA, Barrett JC (2002) Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. Mol Biol Cell 13:2585–2597
Schiedner G, Hertel S, Kochanek S (2000) Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 11:2105–2116
Kramer MG, Barajas M, Razquin N, Berraondo P, Rodrigo M, Wu C et al (2003) In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther 7:375–385
Qian C, Bilbao R, Bruna O, Prieto J (1995) Induction of sensitivity to ganciclovir in human hepatocellular carcinoma cells by adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase. Hepatology 22:118–123
Mazzolini G, Qian C, Narvaiza I, Barajas M, Borras-Cuesta F, Xie X et al (2000) Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum Gene Ther 11:113–125
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B (1998) A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 95:2509–2514
Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 92:9363–9367
Acknowledgements
We thank Izumi Horikawa (National Cancer Institute, Bethesda, MD) for the pBT-255 and pBT-255-4DEB plasmids, Helena Villanueva for technical assistance, Javier Dotor for the FJD cells and Michel Centelles for assistance with flow cytometry. This work was supported by grant SAF2003-08385 from the Spanish Department of Science and Technology and the UTE project CIMA. RHA is a recipient of a Ramon y Cajal research contract. MGK is a recipient of a Fondo de Investigacion Sanitaria (FIS) research contract.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bortolanza, S., Qian, C., Kramer, M.G. et al. An oncolytic adenovirus controlled by a modified telomerase promoter is attenuated in telomerase-negative cells, but shows reduced activity in cancer cells. J Mol Med 83, 736–747 (2005). https://doi.org/10.1007/s00109-005-0681-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-005-0681-1